TICKERNERD
Menu
ZTSZTSHealthcare · Drug Manufacturers - Specialty & Generic

ZTS Stock Forecast: Zoetis, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$73
+0.15% on the day

The 18 Wall Street analysts covering Zoetis, Inc. hold a median 12-month price target of $94 — +28.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$30.2B
Ticker Nerd rank
43 / 100
Median analyst target
$94
Analysts covering
18
Revenue$2.5B+0.3% y/y
Operating income$999.0M
Net income$691.0M
Free cash flow$538.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.4%
1M
−3.2%
YTD
−41.1%
1Y
−50.6%
From 52W high
−50.6%
From 52W low
+2.2%
$71
$148
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zoetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
98
Quality
96
Issuance
51
Growth
48
Accruals
38
Revisions
32
Size
8
Momentum
7

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26ZTSHigh $155Median $94Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
9 Buy9 Hold0 Sell
Low $80Median $94High $155

The green dot is the last close — the median target sits +28.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
25 Aug 2026TD CowenMaintainsBuy$104 → $94
20 Aug 2026StifelMaintainsHold$85 → $80
11 Aug 2026BNP ParibasMaintainsOutperform—
11 Aug 2026BNP ParibasMaintainsOutperform$146 → $110
11 Aug 2026CitigroupMaintainsBuy—
11 Aug 2026CitigroupMaintainsBuy$112 → $96
10 Aug 2026Piper SandlerMaintainsNeutral$90 → $80
10 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$130 → $115
7 Aug 2026UBSMaintainsNeutral—
7 Aug 2026UBSMaintainsNeutral$85 → $80
6 Aug 2026William BlairDowngradeMarket Perform—
6 Aug 2026William BlairDowngradeMarket Perform—
27 July 2026UBSMaintainsNeutral$99 → $85
27 July 2026UBSMaintainsNeutral—
22 July 2026Morgan StanleyMaintainsOverweight$115 → $99
22 July 2026Morgan StanleyMaintainsOverweight—
6 July 2026HSBCMaintainsBuy—
6 July 2026HSBCMaintainsBuy$140 → $95

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Zoetis, Inc. returned −50.6% against +17.5% for the S&P 500, dividends included.

ZTS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ZTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−10.1%
Analysts raising
0
Analysts cutting
15
Fundamentals

Zoetis, Inc. (ZTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.9×

Cheaper than 54% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
9.7×

Cheaper than 10% of US stocks

EV / EBITDA
9.3×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
−0.2%

Higher than 27% of US stocks

Earnings growth (YoY)
−4.8%

Higher than 30% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
40.7%

Higher than 92% of US stocks

Net margin
27.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
64.9%

Higher than 94% of US stocks

Return on assets
15.4%

Higher than 97% of US stocks

Dividend yield
2.9%

Higher than 62% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zoetis, Inc. (ZTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zoetis, Inc. has a market value of $30.2B and an enterprise value of $37.7B.

  • Revenue in the twelve months to 30 June 2026: $9.5B. The latest quarter shrank 0.2% year on year.

  • Net income over the same four quarters: $2.6B, a 27.5% net margin.

  • Diluted earnings per share, trailing twelve months: $6.07.

  • Free cash flow in the twelve months to 30 June 2026: $2.3B, after $524.0M of capital spending.

  • Zoetis, Inc. spent $3.6B on share buybacks and $889.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 414.2M.

  • Trailing P/E: 11.9×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.90%, paying out 34% of earnings.

  • Zoetis, Inc. employs 14,500 people — $656K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ZTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ZTSZoetis, Inc.$30.2B
43
UTHRUnited Therapeutics Corp.$21.1B
82
VTRSViatris, Inc.$19.0B
100
NBIXNeurocrine Biosciences, Inc.$15.6B
89
ELANElanco Animal Health, Inc.$11.6B
98
ALKSAlkermes Plc$7.6B
62
LNTHLantheus Holdings, Inc.$6.5B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zoetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZTS news & analysis

‘Big Short' Michael Burry just updated his portfolio for September

Finbold · 9 Sept 2026neutral

Michael Burry, the hedge fund manager known for predicting the 2008 financial crash, has updated his portfolio for September, with new positions drawing market attention. The report highlights his latest portfolio changes without specifying which companies were affected.

Why it matters — A Zoetis watcher would care because if Burry's updated holdings include ZTS, his buying or selling activity could signal how a prominent investor views the stock.

Top 25 High-Growth Dividend Stocks For September 2026

Seeking Alpha · 2 Sept 2026neutral

Seeking Alpha published its September 2026 Top 25 High-Growth Dividend Stocks list, which targets quality companies trading below intrinsic value with strong long-term return potential. The list groups stocks into Deep Value, Growth At A Price, and Balanced Opportunities categories and reports an average starting yield of 1.21%, an estimated 23% undervaluation by dividend yield theory, and a projected 22.43% annualized long-term return.

Why it matters — A ZTS watcher would care because the article's list of high-growth dividend stocks may or may not include Zoetis, and its valuation criteria reflect the kind of framework investors use to assess the stock.

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Business Wire · 2 Sept 2026neutral

Zoetis announced that CEO Kristin Peck and CFO/COO Jay Saccaro will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 at 1:50 p.m. ET. A live audio webcast will be available on Zoetis' investor relations website, with a replay to follow.

Why it matters — A ZTS watcher would care because the executives' presentation offers an opportunity to hear directly from leadership regarding the company's business at a major industry conference.

Zoetis: A Solid Long-Term Buy After Harsh Drawdown

Seeking Alpha · 18 Aug 2026positive

Zoetis is experiencing the worst drawdown in its stock history amid weakening U.S. vet clinic traffic and heightened competition, while protecting its industry-leading profitability through targeted gross-to-net rebates rather than list-price cuts. The stock is trading at a historic low valuation with a significant margin of safety relative to its fair value estimate.

Why it matters — ZTS watchers would care because the report frames the current drawdown and competitive pressures as overdone relative to the company's protected profitability and historically low valuation, relevant for assessing the company's long-term investment case.

Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

Seeking Alpha · 16 Aug 2026negative

Zoetis reported mixed Q2 results and cut its forward guidance, which reduced the stock's margin of safety. Other business segments performed well, partially offsetting weakness in U.S. pet-related sales, and the article notes the risk/reward profile still favors bulls.

Why it matters — ZTS watchers would care because the guidance cut and mixed quarterly results signal cooling momentum in key pet-related sales even as other segments provide some offset.

FAQ

Frequently asked questions about ZTS stock

What is the ZTS stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Zoetis, Inc. have a median 12-month price target of $94, with estimates ranging from $80 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZTS stock a buy right now?

Of the 18 analysts covering Zoetis, Inc., 9 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zoetis, Inc. 43 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZTS?

As at 12 Sept 2026, Zoetis, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ZTS stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +28.8% from the last close, and Ticker Nerd's factor model ranks Zoetis, Inc. 43 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZTS stock forecast for 2030?

No analyst covering Zoetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $155 over the next 12 months.

How has ZTS stock performed over the past year?

Zoetis, Inc. returned -50.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zoetis, Inc. do?

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock.

What is the latest news on ZTS?

The most recent item we track (Finbold, 9 Sept 2026): "‘Big Short' Michael Burry just updated his portfolio for September". Michael Burry, the hedge fund manager known for predicting the 2008 financial crash, has updated his portfolio for September, with new positions drawing market attention. The report highlights his latest portfolio changes without specifying which companies were affected.

Company

About Zoetis, Inc.

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.

CEO Ms. Kristin C. Peck · 14,500 employees · United States · https://www.zoetis.com